As of 2025-05-31, the EV/EBITDA ratio of InnoCare Pharma Ltd (9969.HK) is -26.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 9969.HK's latest enterprise value is 33,021.91 mil HKD. 9969.HK's TTM EBITDA according to its financial statements is -1,236.44 mil HKD. Dividing these 2 quantities gives us the above 9969.HK EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 18.3x - 19.8x | 18.8x |
| Forward P/E multiples | 10.6x - 11.4x | 11.0x |
| Fair Price | (5.77) - 19.78 | 6.55 |
| Upside | -151.3% - 75.7% | -41.9% |
| Date | EV/EBITDA |
| 2025-04-17 | -18.42 |
| 2025-04-16 | -17.01 |
| 2025-04-15 | -17.64 |
| 2025-04-14 | -17.94 |
| 2025-04-11 | -17.39 |
| 2025-04-10 | -17.01 |
| 2025-04-09 | -16.10 |
| 2025-04-08 | -15.53 |
| 2025-04-07 | -15.48 |
| 2025-04-03 | -19.98 |
| 2025-04-02 | -19.78 |
| 2025-04-01 | -20.46 |
| 2025-03-31 | -19.20 |
| 2025-03-28 | -19.47 |
| 2025-03-27 | -18.64 |
| 2025-03-26 | -17.29 |
| 2025-03-25 | -17.46 |
| 2025-03-24 | -17.64 |
| 2025-03-21 | -17.14 |
| 2025-03-20 | -18.77 |
| 2025-03-19 | -19.07 |
| 2025-03-18 | -18.85 |
| 2025-03-17 | -18.97 |
| 2025-03-14 | -18.59 |
| 2025-03-13 | -18.17 |
| 2025-03-12 | -18.29 |
| 2025-03-11 | -19.12 |
| 2025-03-10 | -19.60 |
| 2025-03-07 | -20.73 |
| 2025-03-06 | -20.53 |
| 2025-03-05 | -20.10 |
| 2025-03-04 | -19.95 |
| 2025-03-03 | -19.68 |
| 2025-02-28 | -19.37 |
| 2025-02-27 | -20.58 |
| 2025-02-26 | -18.75 |
| 2025-02-25 | -16.05 |
| 2025-02-24 | -15.73 |
| 2025-02-21 | -15.22 |
| 2025-02-20 | -14.70 |
| 2025-02-19 | -14.52 |
| 2025-02-18 | -14.37 |
| 2025-02-17 | -12.56 |
| 2025-02-14 | -12.66 |
| 2025-02-13 | -10.55 |
| 2025-02-12 | -10.90 |
| 2025-02-11 | -10.47 |
| 2025-02-10 | -11.07 |
| 2025-02-07 | -10.62 |
| 2025-02-06 | -10.70 |